Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis.

Povero D, Pinatel EM, Leszczynska A, Goyal NP, Nishio T, Kim J, Kneiber D, de Araujo Horcel L, Eguchi A, Ordonez PM, Kisseleva T, Feldstein AE.

JCI Insight. 2019 Jun 11;5. pii: 125652. doi: 10.1172/jci.insight.125652.

2.

Novel Drivers of the Inflammatory Response in Liver Injury and Fibrosis.

Wree A, Holtmann TM, Inzaugarat ME, Feldstein AE.

Semin Liver Dis. 2019 May 17. doi: 10.1055/s-0039-1685515. [Epub ahead of print]

PMID:
31100758
3.

Extracellular vesicles, the liquid biopsy of the future.

Eguchi A, Kostallari E, Feldstein AE, Shah VH.

J Hepatol. 2019 Jun;70(6):1292-1294. doi: 10.1016/j.jhep.2019.01.030. Epub 2019 Apr 12. No abstract available.

PMID:
30982591
4.

Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018.

Banales JM, Feldstein AE, Sänger H, Lukacs-Kornek V, Szabo G, Kornek M.

Hepatol Commun. 2019 Jan 2;3(2):305-315. doi: 10.1002/hep4.1300. eCollection 2019 Feb.

5.

Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects.

Newfield RS, Graves CL, Newbury RO, Schwimmer JB, Proudfoot JA, Say DS, Feldstein AE.

Pediatr Diabetes. 2019 Feb;20(1):41-47. doi: 10.1111/pedi.12798. Epub 2018 Dec 9.

PMID:
30467936
6.

Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases.

Eguchi A, Feldstein AE.

Liver Res. 2018 Mar;2(1):30-34. doi: 10.1016/j.livres.2018.01.001. Epub 2018 Feb 28.

7.

Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis.

Maricic I, Marrero I, Eguchi A, Nakamura R, Johnson CD, Dasgupta S, Hernandez CD, Nguyen PS, Swafford AD, Knight R, Feldstein AE, Loomba R, Kumar V.

J Immunol. 2018 Nov 15;201(10):3017-3035. doi: 10.4049/jimmunol.1800614. Epub 2018 Oct 15.

PMID:
30322964
8.

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.

Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE.

PLoS One. 2018 Oct 4;13(10):e0205541. doi: 10.1371/journal.pone.0205541. eCollection 2018.

9.

Ethanol and unsaturated dietary fat induce unique patterns of hepatic ω-6 and ω-3 PUFA oxylipins in a mouse model of alcoholic liver disease.

Warner DR, Liu H, Ghosh Dastidar S, Warner JB, Prodhan MAI, Yin X, Zhang X, Feldstein AE, Gao B, Prough RA, McClain CJ, Kirpich IA.

PLoS One. 2018 Sep 26;13(9):e0204119. doi: 10.1371/journal.pone.0204119. eCollection 2018.

10.

Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut.

Marrero I, Maricic I, Feldstein AE, Loomba R, Schnabl B, Rivera-Nieves J, Eckmann L, Kumar V.

Front Immunol. 2018 Sep 11;9:2082. doi: 10.3389/fimmu.2018.02082. eCollection 2018. Review.

11.

NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice.

Inzaugarat ME, Johnson CD, Holtmann TM, McGeough MD, Trautwein C, Papouchado BG, Schwabe R, Hoffman HM, Wree A, Feldstein AE.

Hepatology. 2019 Feb;69(2):845-859. doi: 10.1002/hep.30252. Epub 2019 Jan 3.

PMID:
30180270
12.

Liquid biopsy for liver diseases.

Mann J, Reeves HL, Feldstein AE.

Gut. 2018 Dec;67(12):2204-2212. doi: 10.1136/gutjnl-2017-315846. Epub 2018 Sep 3. Review.

PMID:
30177542
13.

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.

Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE.

PLoS One. 2018 Aug 30;13(8):e0202226. doi: 10.1371/journal.pone.0202226. eCollection 2018. Erratum in: PLoS One. 2018 Oct 4;13(10):e0205541.

14.

Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice.

Schuster S, Johnson CD, Hennebelle M, Holtmann T, Taha AY, Kirpich IA, Eguchi A, Ramsden CE, Papouchado BG, McClain CJ, Feldstein AE.

J Lipid Res. 2018 Sep;59(9):1597-1609. doi: 10.1194/jlr.M083741. Epub 2018 Jul 3.

15.

Effects of diets enriched in linoleic acid and its peroxidation products on brain fatty acids, oxylipins, and aldehydes in mice.

Ramsden CE, Hennebelle M, Schuster S, Keyes GS, Johnson CD, Kirpich IA, Dahlen JE, Horowitz MS, Zamora D, Feldstein AE, McClain CJ, Muhlhausler BS, Makrides M, Gibson RA, Taha AY.

Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1206-1213. doi: 10.1016/j.bbalip.2018.07.007. Epub 2018 Jul 25.

16.

Triggering and resolution of inflammation in NASH.

Schuster S, Cabrera D, Arrese M, Feldstein AE.

Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364. doi: 10.1038/s41575-018-0009-6. Review.

PMID:
29740166
17.

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation.

Eguchi A, Koyama Y, Wree A, Johnson CD, Nakamura R, Povero D, Kneiber D, Tameda M, Contreras P, Spada A, Feldstein AE.

J Mol Med (Berl). 2018 Jun;96(6):575-583. doi: 10.1007/s00109-018-1642-9. Epub 2018 May 5.

18.

Role of Nutrition in Alcoholic Liver Disease: Summary of the Symposium at the ESBRA 2017 Congress.

Kharbanda KK, Ronis MJJ, Shearn CT, Petersen DR, Zakhari S, Warner DR, Feldstein AE, McClain CJ, Kirpich IA.

Biomolecules. 2018 Mar 26;8(2). pii: E16. doi: 10.3390/biom8020016.

19.

NASH-RELATED CIRRHOSIS: AN OCCULT LIVER DISEASE BURDEN.

Arrese M, Feldstein AE.

Hepatol Commun. 2017 Apr;1(2):84-86. doi: 10.1002/hep4.1033. Epub 2017 Apr 6. No abstract available.

20.

TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies.

McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD, Peña CA, Goldbach-Mansky R, Broderick L, Feldstein AE, Hoffman HM.

J Clin Invest. 2017 Dec 1;127(12):4488-4497. doi: 10.1172/JCI90699. Epub 2017 Nov 13.

21.

Dietary Linoleic Acid and Its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Proinflammatory Response in Mice.

Warner DR, Liu H, Miller ME, Ramsden CE, Gao B, Feldstein AE, Schuster S, McClain CJ, Kirpich IA.

Am J Pathol. 2017 Oct;187(10):2232-2245. doi: 10.1016/j.ajpath.2017.06.008.

22.

NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.

Wree A, McGeough MD, Inzaugarat ME, Eguchi A, Schuster S, Johnson CD, Peña CA, Geisler LJ, Papouchado BG, Hoffman HM, Feldstein AE.

Hepatology. 2017 Sep 13. doi: 10.1002/hep.29523. [Epub ahead of print]

23.

Transmembrane BAX Inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment.

Wree A, Inzaugarat ME, Feldstein AE.

Hepatology. 2018 Jan;67(1):438-441. doi: 10.1002/hep.29495. No abstract available.

24.

Traffic-related air pollution associations with cytokeratin-18, a marker of hepatocellular apoptosis, in an overweight and obese paediatric population.

Hsieh S, Leaderer BP, Feldstein AE, Santoro N, McKay LA, Caprio S, McConnell R.

Pediatr Obes. 2018 Jun;13(6):342-347. doi: 10.1111/ijpo.12228. Epub 2017 Jul 20.

25.

Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis.

Cabrera D, Wree A, Povero D, Solís N, Hernandez A, Pizarro M, Moshage H, Torres J, Feldstein AE, Cabello-Verrugio C, Brandan E, Barrera F, Arab JP, Arrese M.

Sci Rep. 2017 Jun 14;7(1):3491. doi: 10.1038/s41598-017-03675-z.

26.

Inflammasomes in Liver Fibrosis.

Alegre F, Pelegrin P, Feldstein AE.

Semin Liver Dis. 2017 May;37(2):119-127. doi: 10.1055/s-0037-1601350. Epub 2017 May 31. Review.

PMID:
28564720
27.

NASH: Novel therapeutic strategies targeting ASK1 in NASH.

Schuster S, Feldstein AE.

Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):329-330. doi: 10.1038/nrgastro.2017.42. Epub 2017 Apr 5. No abstract available.

PMID:
28377639
28.

Oxidized Derivatives of Linoleic Acid in Pediatric Metabolic Syndrome: Is Their Pathogenic Role Modulated by the Genetic Background and the Gut Microbiota?

Tricò D, Di Sessa A, Caprio S, Chalasani N, Liu W, Liang T, Graf J, Herzog RI, Johnson CD, Umano GR, Feldstein AE, Santoro N.

Antioxid Redox Signal. 2017 Apr 7. doi: 10.1089/ars.2017.7049. [Epub ahead of print]

PMID:
28279074
29.

Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis.

Cannito S, Morello E, Bocca C, Foglia B, Benetti E, Novo E, Chiazza F, Rogazzo M, Fantozzi R, Povero D, Sutti S, Bugianesi E, Feldstein AE, Albano E, Collino M, Parola M.

PLoS One. 2017 Mar 1;12(3):e0172575. doi: 10.1371/journal.pone.0172575. eCollection 2017.

30.

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC.

J Hepatol. 2017 May;66(5):1037-1046. doi: 10.1016/j.jhep.2017.01.022. Epub 2017 Feb 3.

31.

Treating nonalcoholic steatohepatitis in children: Not a cinch task.

Alkhouri N, Feldstein AE.

Hepatology. 2017 Apr;65(4):1407-1409. doi: 10.1002/hep.29043. No abstract available.

PMID:
28073147
32.

Update on lipid species and paediatric nonalcoholic fatty liver disease.

Mann JP, Feldstein AE, Nobili V.

Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):110-116. doi: 10.1097/MCO.0000000000000346. Review.

PMID:
27906700
33.

Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress.

Eguchi A, Lazic M, Armando AM, Phillips SA, Katebian R, Maraka S, Quehenberger O, Sears DD, Feldstein AE.

J Mol Med (Berl). 2016 Nov;94(11):1241-1253. doi: 10.1007/s00109-016-1446-8. Epub 2016 Jul 9.

34.

Fatty liver in adolescents: Mechanisms, clinical features and therapy.

Nobili V, Feldstein AE.

J Hepatol. 2016 Dec;65(6):1258-1260. doi: 10.1016/j.jhep.2016.07.036. Epub 2016 Oct 11. No abstract available.

PMID:
27742132
35.

Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.

Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE.

Hepatology. 2017 Feb;65(2):475-490. doi: 10.1002/hep.28838. Epub 2016 Nov 10.

36.

Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis.

Inzaugarat ME, Wree A, Feldstein AE.

Hepatology. 2016 Aug;64(2):669-71. doi: 10.1002/hep.28666. Epub 2016 Jun 24. No abstract available.

37.

Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?

Alkhouri N, Feldstein AE.

Metabolism. 2016 Aug;65(8):1087-95. doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2. Review.

38.

Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.

Crespo M, Lappe S, Feldstein AE, Alkhouri N.

Metabolism. 2016 Aug;65(8):1161-71. doi: 10.1016/j.metabol.2016.01.008. Epub 2016 Jan 20. Review.

PMID:
26961580
39.

Soluble IgM links apoptosis to complement activation in early alcoholic liver disease in mice.

Smathers RL, Chiang DJ, McMullen MR, Feldstein AE, Roychowdhury S, Nagy LE.

Mol Immunol. 2016 Apr;72:9-18. doi: 10.1016/j.molimm.2016.02.008. Epub 2016 Feb 27.

40.

Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis.

Povero D, Feldstein AE.

Diabetes Metab J. 2016 Feb;40(1):1-11. doi: 10.4093/dmj.2016.40.1.1. Review.

41.

Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.

Wree A, Mehal WZ, Feldstein AE.

Semin Liver Dis. 2016 Feb;36(1):27-36. doi: 10.1055/s-0035-1571272. Epub 2016 Feb 12. Review.

42.

Innate Immunity and Inflammation in NAFLD/NASH.

Arrese M, Cabrera D, Kalergis AM, Feldstein AE.

Dig Dis Sci. 2016 May;61(5):1294-303. doi: 10.1007/s10620-016-4049-x. Epub 2016 Feb 3. Review.

43.

Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ.

Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V, Feldstein AE.

Cell Mol Gastroenterol Hepatol. 2015 Nov 1;1(6):646-663.e4.

44.

Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis.

Eguchi A, De Mollerat Du Jeu X, Johnson CD, Nektaria A, Feldstein AE.

J Hepatol. 2016 Mar;64(3):699-707. doi: 10.1016/j.jhep.2015.11.002. Epub 2015 Nov 7.

45.

Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.

Goffredo M, Caprio S, Feldstein AE, D'Adamo E, Shaw MM, Pierpont B, Savoye M, Zhao H, Bale AE, Santoro N.

Hepatology. 2016 Jan;63(1):117-25. doi: 10.1002/hep.28283. Epub 2015 Nov 16.

46.

Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center.

Kathemann S, Bechmann LP, Sowa JP, Manka P, Dechêne A, Gerner P, Lainka E, Hoyer PF, Feldstein AE, Canbay A.

Ann Hepatol. 2015 Sep-Oct;14(5):722-8.

47.

Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort.

Pan JJ, Fisher-Hoch SP, Chen C, Feldstein AE, McCormick JB, Rahbar MH, Beretta L, Fallon MB.

World J Hepatol. 2015 Jun 18;7(11):1586-94. doi: 10.4254/wjh.v7.i11.1586.

48.

Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis.

Eguchi A, Yoshitomi T, Lazic M, Johnson CD, Vong LB, Wree A, Povero D, Papouchado BG, Nagasaki Y, Feldstein AE.

Nanomedicine (Lond). 2015;10(17):2697-708. doi: 10.2217/nnm.15.87. Epub 2015 May 28.

49.

Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD.

Nagpal SJ, Lopez R, Feldstein AE, Alkhouri N.

Liver Int. 2015 Dec;35(12):2621. doi: 10.1111/liv.12862. Epub 2015 May 21. No abstract available.

PMID:
25939859
50.

Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE.

Cell Death Differ. 2015 Dec;22(12):1985-94. doi: 10.1038/cdd.2015.46. Epub 2015 Apr 24.

Supplemental Content

Loading ...
Support Center